These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36071989)

  • 1. Exploring Adverse Events and Utilization of Topical Hemostatic Agents in Surgery.
    O'Hanlan KA; Bassett P
    JSLS; 2022; 26(3):. PubMed ID: 36071989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a randomised controlled trial between an ORC collagen hemostatic agent and a carrier-bound fibrin sealant.
    Pallaske F; Seebauer C; Kaltofen D; Dziomber S; Rudolph H; Schwanebeck U; Grählert X; Schulze G; Pallaske A; Boese-Landgraf J; Schlömann M; Daeschlein G
    J Visc Surg; 2021 Feb; 158(1):11-18. PubMed ID: 32747306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Hemostatic Efficacy of Two Powdered Topical Absorbable Hemostats Using a Porcine Liver Abrasion Model of Mild to Moderate Bleeding.
    MacDonald MH; Tasse L; Wang D; Zhang G; De Leon H; Kocharian R
    J Invest Surg; 2021 Nov; 34(11):1198-1206. PubMed ID: 32928005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, Single-Blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Soft Tissue Open Surgery.
    Lakshman S; Aqua K; Stefanovic A; Djurdjevic S; Nyirády P; Osváth P; Davis R; Bullock A; Chen J; Ibañez J; Barrera G; Navarro-Puerto J;
    J Invest Surg; 2020 Mar; 33(3):218-230. PubMed ID: 30303427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a new fibrin sealant with standard topical hemostatic agents.
    Schwartz M; Madariaga J; Hirose R; Shaver TR; Sher L; Chari R; Colonna JO; Heaton N; Mirza D; Adams R; Rees M; Lloyd D
    Arch Surg; 2004 Nov; 139(11):1148-54. PubMed ID: 15545559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Reported Adverse Events Related to Hemospray: An FDA MAUDE Database Study.
    Ahmed K; Abdallah M; Abbas D; Jaber F; Abdalla AO; Mohamed M; McDonald N; Hanson BJ; Bilal M
    J Clin Gastroenterol; 2024 Apr; 58(4):402-406. PubMed ID: 37267458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter clinical trial to evaluate the topical hemostatic efficacy of fibrin sealant in burn patients.
    Nervi C; Gamelli RL; Greenhalgh DG; Luterman A; Hansbrough JF; Achauer BM; Gomperts ED; Lee M; Navalta L; Cruciani TR
    J Burn Care Rehabil; 2001; 22(2):99-103. PubMed ID: 11302613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic efficacy of EVARREST™, Fibrin Sealant Patch vs. TachoSil® in a heparinized swine spleen incision model.
    Matonick JP; Hammond J
    J Invest Surg; 2014 Dec; 27(6):360-5. PubMed ID: 25361019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models.
    MacDonald MH; Wang AY; Clymer JW; Hutchinson RW; Kocharian R
    Med Devices (Auckl); 2017; 10():273-279. PubMed ID: 29238233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of a dry-powder, fibrin sealant in vascular procedures.
    Gupta N; Chetter I; Hayes P; O-Yurvati AH; Moneta GL; Shenoy S; Pribble JP; Zuckerman LA
    J Vasc Surg; 2015 Nov; 62(5):1288-95. PubMed ID: 26254451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage.
    Chan MW; Schwaitzberg SD; Demcheva M; Vournakis J; Finkielsztein S; Connolly RJ
    J Trauma; 2000 Mar; 48(3):454-7; discussion 457-8. PubMed ID: 10744283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.
    Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ
    Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective, Randomized, Multicenter Clinical Trial on the Safety and Efficacy of a Ready-to-Use Fibrin Sealant as an Adjunct to Hemostasis during Vascular Surgery.
    Chetter I; Stansby G; Sarralde JA; Riambau V; Giménez-Gaibar A; MacKenzie K; Acín F; Navarro-Puerto J;
    Ann Vasc Surg; 2017 Nov; 45():127-137. PubMed ID: 28647631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemostatic effect of oxidized regenerated cellulose in an experimental gastric mucosal resection model.
    Velázquez-Aviña J; Mönkemüller K; Sakai P; Sulbaran M; Chávez-Vargas C; Montalvo Javé E; Sobrino-Cossío S
    Endoscopy; 2014 Oct; 46(10):878-82. PubMed ID: 25225961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of five standard topical hemostats: a study in porcine liver and spleen models of surgical bleeding.
    Paternò VA; Bisin A; Addis A
    BMC Surg; 2020 Sep; 20(1):215. PubMed ID: 32977788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a liquid fibrin sealant with sheet-type hemostatic agents: experimental evaluation in partial nephrectomy animal model.
    Ishii K; Kawashima H; Hayama T; Asai T; Kamikawa S; Sakamoto W; Miyabashira S; Oka S; Sugimoto T
    Int J Urol; 2011 Jun; 18(6):478-82. PubMed ID: 21488977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the efficacy of the common topical hemostatic agents with fibrin sealant in a rabbit aortic anastomosis model.
    Kheirabadi BS; Field-Ridley A; Pearson R; MacPhee M; Drohan W; Tuthill D
    J Surg Res; 2002 Jul; 106(1):99-107. PubMed ID: 12127814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, double-blind clinical study.
    Lowe J; Luber J; Levitsky S; Hantak E; Montgomery J; Schiestl N; Schofield N; Marra S;
    J Cardiovasc Surg (Torino); 2007 Jun; 48(3):323-31. PubMed ID: 17505437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of reported StarClose SE vascular closure device complications in the manufacturer and user facility device experience database.
    Johnson DT; Durack JC; Fidelman N; Kerlan RK; LaBerge JM
    J Vasc Interv Radiol; 2013 Jul; 24(7):1051-6. PubMed ID: 23796092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents.
    Lewis KM; Spazierer D; Urban MD; Lin L; Redl H; Goppelt A
    Eur Surg; 2013; 45(4):213-220. PubMed ID: 23950762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.